Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Homocysteine and Asymmetric Dimethylarginine

Research Papers that Mention the Interaction

There is evidence that an increase in plasma homocysteine may increase the formation of asymmetric dimethylarginine ( ADMA ), an inhibitor of nitric oxide synthase.
Metabolism: clinical and experimental  •  2005  |  View Paper
Our results suggest that ADMA may be a mediator of the atherogenic effects of homocysteine.
British Journal of Nutrition  •  2003  |  View Paper
In the combined patient and control groups a highly significant positive correlation was found between the plasma concentrations of homocysteine and ADMA (r=0.782, P<0.0001).
Neurobiology of Aging  •  2003  |  View Paper
Homocysteine has been proposed to inhibit the catabolic enzyme of ADMA , dimethylarginine dimethylaminohydrolase (DDAH), but the mechanism of this inhibition has not been fully elucidated.
Journal of Biological Chemistry  •  2007  |  View Paper
Finally, homocysteine , either directly or by increasing oxidative stress, may promote release of free ADMA by accelerating protein degradation.
The metabolic pathways of ADMA and homocysteine are strongly intertwined.
Clinical chemistry and laboratory medicine  •  2005  |  View Paper
There is experimental evidence that homocysteine may affect endothelium-dependent vascular function by increasing the formation of ADMA.
Clinical chemistry and laboratory medicine  •  2003  |  View Paper
ADMA release by cultured endothelial cells was significantly increased in the presence of methionine or homocysteine.
Arteriosclerosis, thrombosis, and vascular biology  •  2000  |  View Paper
Conclusions: Hcy and ADMA are significantly associated in RA.
Scandinavian journal of rheumatology  •  2016  |  View Paper
It has been suggested that homocysteine leads to endothelial dysfunction by causing an accumulation of asymmetrical dimethyl arginine (ADMA), a potent endogenous nitric oxide (NO) synthase inhibitor of the l-arginine–NO pathway.
Archives of Dermatological Research  •  2015  |  View Paper
HCY has been shown to inhibit the activity of endothelial dimethylaminohydrolase (DDAH), causing the accumulation of ADMA and the inhibition of nitric oxide synthesis.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences  •  2013  |  View Paper
Show More